Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Botswana | 116 | 2024 | 1040 | 4.730 |
Why?
|
HIV Infections | 134 | 2024 | 17165 | 3.830 |
Why?
|
HIV-1 | 73 | 2024 | 6849 | 3.810 |
Why?
|
Anti-HIV Agents | 49 | 2024 | 4491 | 2.280 |
Why?
|
Viral Load | 41 | 2024 | 3322 | 2.050 |
Why?
|
Drug Resistance, Viral | 20 | 2024 | 859 | 2.030 |
Why?
|
RNA, Viral | 23 | 2021 | 2838 | 1.640 |
Why?
|
HIV Seropositivity | 15 | 2023 | 955 | 1.630 |
Why?
|
Hepatitis B | 12 | 2024 | 701 | 1.260 |
Why?
|
Anti-Retroviral Agents | 18 | 2023 | 1779 | 1.200 |
Why?
|
Infectious Disease Transmission, Vertical | 21 | 2024 | 1348 | 1.140 |
Why?
|
Hepatitis B virus | 12 | 2024 | 522 | 1.110 |
Why?
|
Alphapapillomavirus | 5 | 2022 | 218 | 1.040 |
Why?
|
Pregnancy Complications, Infectious | 22 | 2024 | 2125 | 0.980 |
Why?
|
Wolves | 1 | 2023 | 10 | 0.880 |
Why?
|
Phylogeny | 22 | 2024 | 2775 | 0.860 |
Why?
|
Reverse Transcriptase Inhibitors | 6 | 2022 | 618 | 0.850 |
Why?
|
Papillomavirus Infections | 8 | 2024 | 1607 | 0.830 |
Why?
|
Dog Diseases | 1 | 2023 | 141 | 0.820 |
Why?
|
Genotype | 34 | 2024 | 12960 | 0.770 |
Why?
|
Antiretroviral Therapy, Highly Active | 18 | 2024 | 1894 | 0.760 |
Why?
|
Heterocyclic Compounds, 3-Ring | 7 | 2024 | 279 | 0.750 |
Why?
|
Molecular Diagnostic Techniques | 2 | 2016 | 611 | 0.740 |
Why?
|
HIV Reverse Transcriptase | 2 | 2019 | 212 | 0.690 |
Why?
|
HIV Antigens | 2 | 2018 | 325 | 0.660 |
Why?
|
CD4 Lymphocyte Count | 19 | 2023 | 2569 | 0.620 |
Why?
|
Hepatitis B Surface Antigens | 7 | 2024 | 301 | 0.620 |
Why?
|
Oxazines | 8 | 2024 | 341 | 0.610 |
Why?
|
Serologic Tests | 2 | 2018 | 383 | 0.570 |
Why?
|
Meningitis, Cryptococcal | 3 | 2022 | 66 | 0.560 |
Why?
|
Hepatitis Delta Virus | 3 | 2024 | 24 | 0.540 |
Why?
|
gag Gene Products, Human Immunodeficiency Virus | 5 | 2020 | 206 | 0.520 |
Why?
|
Caliciviridae Infections | 3 | 2021 | 29 | 0.520 |
Why?
|
Antibody Affinity | 1 | 2016 | 245 | 0.510 |
Why?
|
Zidovudine | 9 | 2024 | 624 | 0.510 |
Why?
|
Pyridones | 8 | 2024 | 792 | 0.490 |
Why?
|
Hepatitis D | 2 | 2024 | 23 | 0.480 |
Why?
|
Mutation | 24 | 2024 | 29932 | 0.480 |
Why?
|
Uterine Cervical Dysplasia | 4 | 2024 | 384 | 0.460 |
Why?
|
Lamivudine | 5 | 2024 | 363 | 0.450 |
Why?
|
HIV Antibodies | 9 | 2023 | 1300 | 0.440 |
Why?
|
HIV | 12 | 2023 | 1579 | 0.440 |
Why?
|
Uterine Cervical Neoplasms | 5 | 2024 | 2003 | 0.430 |
Why?
|
DNA, Viral | 13 | 2023 | 2194 | 0.430 |
Why?
|
Immunoassay | 1 | 2016 | 746 | 0.420 |
Why?
|
Viremia | 5 | 2024 | 707 | 0.420 |
Why?
|
Breast Feeding | 8 | 2021 | 1355 | 0.410 |
Why?
|
Genetic Variation | 9 | 2022 | 6551 | 0.410 |
Why?
|
Nevirapine | 8 | 2024 | 273 | 0.400 |
Why?
|
Prevalence | 24 | 2024 | 15687 | 0.380 |
Why?
|
Hepatitis B Antibodies | 5 | 2023 | 157 | 0.380 |
Why?
|
Adult | 90 | 2024 | 219994 | 0.370 |
Why?
|
HIV Integrase Inhibitors | 3 | 2024 | 165 | 0.360 |
Why?
|
Proviruses | 5 | 2023 | 313 | 0.350 |
Why?
|
Humans | 157 | 2024 | 760621 | 0.350 |
Why?
|
Norovirus | 2 | 2021 | 36 | 0.340 |
Why?
|
Molecular Typing | 3 | 2019 | 116 | 0.330 |
Why?
|
Female | 106 | 2024 | 391270 | 0.330 |
Why?
|
Hepatitis B, Chronic | 2 | 2023 | 403 | 0.330 |
Why?
|
Diagnostic Errors | 1 | 2016 | 1266 | 0.320 |
Why?
|
Piperazines | 7 | 2024 | 2525 | 0.310 |
Why?
|
Circumcision, Male | 2 | 2020 | 148 | 0.310 |
Why?
|
Pregnancy | 36 | 2024 | 29749 | 0.310 |
Why?
|
Leukocytes, Mononuclear | 6 | 2023 | 1827 | 0.300 |
Why?
|
Cross-Sectional Studies | 21 | 2023 | 25942 | 0.290 |
Why?
|
Tuberculosis | 4 | 2023 | 2001 | 0.290 |
Why?
|
env Gene Products, Human Immunodeficiency Virus | 3 | 2023 | 368 | 0.280 |
Why?
|
Infant, Newborn | 24 | 2024 | 26181 | 0.280 |
Why?
|
Benzoxazines | 6 | 2024 | 309 | 0.270 |
Why?
|
Infant Formula | 3 | 2018 | 193 | 0.260 |
Why?
|
Young Adult | 34 | 2024 | 58741 | 0.250 |
Why?
|
Infant Mortality | 4 | 2019 | 757 | 0.250 |
Why?
|
Mutation, Missense | 4 | 2018 | 2566 | 0.240 |
Why?
|
Maternal Mortality | 2 | 2024 | 300 | 0.240 |
Why?
|
Alkynes | 5 | 2024 | 313 | 0.240 |
Why?
|
Receptors, CXCR4 | 3 | 2016 | 728 | 0.230 |
Why?
|
Incidence | 14 | 2023 | 21392 | 0.230 |
Why?
|
Drug Resistance, Multiple, Viral | 2 | 2018 | 53 | 0.230 |
Why?
|
Carcinoma, Squamous Cell | 2 | 2019 | 4024 | 0.230 |
Why?
|
Male | 65 | 2024 | 359744 | 0.230 |
Why?
|
Cyclopropanes | 5 | 2024 | 431 | 0.230 |
Why?
|
Cytomegalovirus Infections | 3 | 2020 | 831 | 0.220 |
Why?
|
Infant | 24 | 2024 | 36060 | 0.210 |
Why?
|
Epidemics | 3 | 2022 | 510 | 0.210 |
Why?
|
AIDS-Related Opportunistic Infections | 3 | 2020 | 662 | 0.210 |
Why?
|
Middle Aged | 47 | 2024 | 220352 | 0.210 |
Why?
|
Rural Population | 5 | 2024 | 2268 | 0.200 |
Why?
|
HIV Envelope Protein gp120 | 5 | 2016 | 915 | 0.200 |
Why?
|
Dideoxynucleosides | 2 | 2012 | 132 | 0.200 |
Why?
|
Human papillomavirus 18 | 2 | 2019 | 125 | 0.190 |
Why?
|
Receptors, HIV | 2 | 2016 | 159 | 0.190 |
Why?
|
Public Policy | 2 | 2016 | 560 | 0.190 |
Why?
|
Papillomaviridae | 2 | 2024 | 1117 | 0.190 |
Why?
|
Sapovirus | 1 | 2020 | 4 | 0.180 |
Why?
|
Latent Tuberculosis | 1 | 2023 | 224 | 0.180 |
Why?
|
Immunoenzyme Techniques | 3 | 2013 | 1705 | 0.180 |
Why?
|
Human papillomavirus 16 | 2 | 2019 | 265 | 0.180 |
Why?
|
Condoms | 3 | 2022 | 315 | 0.180 |
Why?
|
Gastroenteritis | 2 | 2020 | 237 | 0.170 |
Why?
|
Mass Screening | 5 | 2020 | 5423 | 0.170 |
Why?
|
Insulin Resistance | 2 | 2024 | 3959 | 0.170 |
Why?
|
Tetanus Toxoid | 1 | 2020 | 193 | 0.170 |
Why?
|
Disease Reservoirs | 1 | 2019 | 121 | 0.170 |
Why?
|
Africa | 4 | 2022 | 705 | 0.170 |
Why?
|
Antigens, Differentiation, Myelomonocytic | 2 | 2018 | 282 | 0.160 |
Why?
|
Adolescent | 21 | 2024 | 87810 | 0.160 |
Why?
|
Hepatitis B Vaccines | 1 | 2020 | 186 | 0.160 |
Why?
|
Adenine | 2 | 2023 | 975 | 0.160 |
Why?
|
Certification | 1 | 2022 | 421 | 0.160 |
Why?
|
Nucleosides | 1 | 2019 | 131 | 0.160 |
Why?
|
HIV Integrase | 1 | 2019 | 121 | 0.160 |
Why?
|
Immune Evasion | 1 | 2022 | 362 | 0.150 |
Why?
|
Dogs | 1 | 2023 | 3841 | 0.150 |
Why?
|
Syphilis | 2 | 2019 | 241 | 0.150 |
Why?
|
Virus Replication | 4 | 2021 | 2432 | 0.150 |
Why?
|
Milk, Human | 2 | 2012 | 483 | 0.150 |
Why?
|
Pregnancy Outcome | 7 | 2024 | 2907 | 0.150 |
Why?
|
Educational Status | 2 | 2016 | 2515 | 0.150 |
Why?
|
Paraffin Embedding | 1 | 2019 | 302 | 0.150 |
Why?
|
Tissue Fixation | 1 | 2019 | 241 | 0.150 |
Why?
|
Virus Activation | 1 | 2019 | 319 | 0.150 |
Why?
|
Premature Birth | 3 | 2022 | 1771 | 0.150 |
Why?
|
Schools | 2 | 2016 | 1480 | 0.140 |
Why?
|
Enzyme Assays | 1 | 2017 | 107 | 0.140 |
Why?
|
Blood Donors | 1 | 2018 | 343 | 0.140 |
Why?
|
Pyridazines | 1 | 2018 | 200 | 0.140 |
Why?
|
Viral Vaccines | 1 | 2022 | 596 | 0.130 |
Why?
|
Cluster Analysis | 4 | 2018 | 2698 | 0.130 |
Why?
|
Genes, env | 2 | 2013 | 95 | 0.130 |
Why?
|
Penile Neoplasms | 1 | 2017 | 162 | 0.130 |
Why?
|
Stillbirth | 3 | 2024 | 368 | 0.130 |
Why?
|
Students | 2 | 2016 | 1730 | 0.130 |
Why?
|
Sequence Analysis, DNA | 7 | 2015 | 4713 | 0.130 |
Why?
|
Longitudinal Studies | 9 | 2020 | 14495 | 0.120 |
Why?
|
Vulvar Neoplasms | 1 | 2017 | 263 | 0.120 |
Why?
|
Pregnancy, Unplanned | 1 | 2016 | 88 | 0.120 |
Why?
|
Evolution, Molecular | 4 | 2013 | 1885 | 0.120 |
Why?
|
Asymptomatic Infections | 1 | 2015 | 131 | 0.120 |
Why?
|
HLA Antigens | 1 | 2020 | 1368 | 0.120 |
Why?
|
Chemoprevention | 1 | 2017 | 326 | 0.120 |
Why?
|
Vascular Diseases | 1 | 2023 | 1182 | 0.120 |
Why?
|
Child Mortality | 1 | 2016 | 205 | 0.110 |
Why?
|
Contraception Behavior | 1 | 2016 | 180 | 0.110 |
Why?
|
Gene Frequency | 2 | 2019 | 3615 | 0.110 |
Why?
|
Anus Neoplasms | 1 | 2017 | 329 | 0.110 |
Why?
|
Cervix Uteri | 3 | 2024 | 582 | 0.110 |
Why?
|
Sexual Partners | 2 | 2018 | 753 | 0.110 |
Why?
|
Pandemics | 3 | 2022 | 8624 | 0.110 |
Why?
|
Hepatitis B e Antigens | 2 | 2023 | 133 | 0.110 |
Why?
|
Sampling Studies | 1 | 2014 | 613 | 0.110 |
Why?
|
South Africa | 3 | 2024 | 1821 | 0.110 |
Why?
|
Immunologic Memory | 1 | 2020 | 1354 | 0.110 |
Why?
|
Treatment Failure | 4 | 2024 | 2648 | 0.100 |
Why?
|
Amino Acid Substitution | 2 | 2020 | 1737 | 0.100 |
Why?
|
Cassia | 1 | 2012 | 3 | 0.100 |
Why?
|
Time Factors | 12 | 2021 | 40165 | 0.100 |
Why?
|
Hepacivirus | 1 | 2019 | 1334 | 0.100 |
Why?
|
Early Diagnosis | 1 | 2017 | 1180 | 0.100 |
Why?
|
Mastitis | 1 | 2012 | 43 | 0.100 |
Why?
|
Host-Pathogen Interactions | 3 | 2016 | 1447 | 0.100 |
Why?
|
Plasma | 1 | 2015 | 584 | 0.100 |
Why?
|
Leukocytes | 1 | 2020 | 2026 | 0.100 |
Why?
|
Prenatal Exposure Delayed Effects | 3 | 2024 | 2496 | 0.100 |
Why?
|
Didanosine | 2 | 2009 | 151 | 0.100 |
Why?
|
Disease Progression | 3 | 2019 | 13502 | 0.100 |
Why?
|
Cell Adhesion Molecules | 1 | 2018 | 1602 | 0.100 |
Why?
|
Diagnostic Tests, Routine | 3 | 2024 | 786 | 0.100 |
Why?
|
Hemoglobins | 1 | 2018 | 1521 | 0.100 |
Why?
|
Specimen Handling | 1 | 2016 | 707 | 0.100 |
Why?
|
Immunity, Humoral | 1 | 2016 | 604 | 0.100 |
Why?
|
Bayes Theorem | 2 | 2017 | 2326 | 0.100 |
Why?
|
Inflammation Mediators | 2 | 2018 | 1881 | 0.100 |
Why?
|
Homosexuality, Male | 2 | 2022 | 1273 | 0.100 |
Why?
|
Attitude to Health | 1 | 2020 | 2029 | 0.090 |
Why?
|
Geography | 1 | 2013 | 661 | 0.090 |
Why?
|
Immunity, Innate | 2 | 2022 | 3047 | 0.090 |
Why?
|
Receptors, Cell Surface | 2 | 2018 | 2825 | 0.090 |
Why?
|
Disease Transmission, Infectious | 1 | 2017 | 558 | 0.090 |
Why?
|
Feasibility Studies | 1 | 2021 | 5201 | 0.090 |
Why?
|
Carotid Artery Diseases | 1 | 2017 | 883 | 0.090 |
Why?
|
Hepatitis C | 2 | 2019 | 1579 | 0.090 |
Why?
|
Early Detection of Cancer | 2 | 2023 | 3202 | 0.090 |
Why?
|
Drug Resistance, Bacterial | 1 | 2017 | 1055 | 0.090 |
Why?
|
Antigens, CD | 2 | 2018 | 4000 | 0.090 |
Why?
|
Interleukin-6 | 3 | 2018 | 3215 | 0.090 |
Why?
|
Viral Tropism | 2 | 2023 | 102 | 0.080 |
Why?
|
Prospective Studies | 9 | 2024 | 54303 | 0.080 |
Why?
|
Cytokines | 2 | 2015 | 7343 | 0.080 |
Why?
|
RNA | 3 | 2023 | 2722 | 0.080 |
Why?
|
Antibodies, Neutralizing | 3 | 2023 | 1933 | 0.080 |
Why?
|
Genomics | 2 | 2022 | 5794 | 0.080 |
Why?
|
Cohort Studies | 13 | 2021 | 41335 | 0.080 |
Why?
|
Retrospective Studies | 14 | 2023 | 80372 | 0.080 |
Why?
|
Pregnancy Complications | 1 | 2022 | 2942 | 0.080 |
Why?
|
Sexually Transmitted Diseases | 1 | 2014 | 628 | 0.080 |
Why?
|
Point-of-Care Systems | 1 | 2017 | 1204 | 0.080 |
Why?
|
E-Selectin | 2 | 2023 | 576 | 0.080 |
Why?
|
Immunoglobulin M | 2 | 2023 | 1529 | 0.080 |
Why?
|
Molecular Sequence Data | 8 | 2014 | 17624 | 0.080 |
Why?
|
Hospitals, District | 1 | 2009 | 113 | 0.080 |
Why?
|
Plant Extracts | 1 | 2012 | 496 | 0.080 |
Why?
|
Sexual Behavior | 2 | 2016 | 2086 | 0.080 |
Why?
|
Vascular Cell Adhesion Molecule-1 | 2 | 2023 | 691 | 0.080 |
Why?
|
Mycobacterium tuberculosis | 1 | 2019 | 1903 | 0.080 |
Why?
|
Sensitivity and Specificity | 3 | 2020 | 14660 | 0.070 |
Why?
|
Prenatal Diagnosis | 1 | 2015 | 1264 | 0.070 |
Why?
|
Thymidine | 1 | 2007 | 299 | 0.070 |
Why?
|
Counseling | 1 | 2015 | 1548 | 0.070 |
Why?
|
Intercellular Adhesion Molecule-1 | 2 | 2023 | 1126 | 0.070 |
Why?
|
Biopsy | 1 | 2019 | 6771 | 0.070 |
Why?
|
RNA-Directed DNA Polymerase | 1 | 2007 | 224 | 0.070 |
Why?
|
Acidosis, Lactic | 1 | 2007 | 145 | 0.070 |
Why?
|
Nitriles | 2 | 2023 | 956 | 0.070 |
Why?
|
Epitopes | 2 | 2023 | 2503 | 0.070 |
Why?
|
Endothelium, Vascular | 1 | 2018 | 4433 | 0.070 |
Why?
|
Triage | 2 | 2023 | 987 | 0.060 |
Why?
|
Antiviral Agents | 3 | 2024 | 3061 | 0.060 |
Why?
|
CD4-Positive T-Lymphocytes | 3 | 2023 | 4353 | 0.060 |
Why?
|
Child, Preschool | 7 | 2024 | 42063 | 0.060 |
Why?
|
Immunocompromised Host | 2 | 2020 | 857 | 0.060 |
Why?
|
Vitamin D Deficiency | 1 | 2014 | 1379 | 0.060 |
Why?
|
Hospitalization | 3 | 2020 | 10790 | 0.060 |
Why?
|
Amino Acid Sequence | 4 | 2020 | 13451 | 0.060 |
Why?
|
Acetic Acid | 1 | 2023 | 60 | 0.060 |
Why?
|
Child | 8 | 2023 | 79806 | 0.060 |
Why?
|
Pre-Eclampsia | 1 | 2013 | 1229 | 0.060 |
Why?
|
Base Sequence | 4 | 2019 | 12446 | 0.050 |
Why?
|
Hepatitis B Core Antigens | 1 | 2023 | 88 | 0.050 |
Why?
|
Parturition | 2 | 2019 | 446 | 0.050 |
Why?
|
Tropism | 1 | 2023 | 43 | 0.050 |
Why?
|
Molecular Epidemiology | 2 | 2015 | 469 | 0.050 |
Why?
|
Colposcopy | 1 | 2023 | 150 | 0.050 |
Why?
|
Prognosis | 3 | 2019 | 29658 | 0.050 |
Why?
|
Computational Biology | 1 | 2015 | 3505 | 0.050 |
Why?
|
Epitopes, T-Lymphocyte | 2 | 2020 | 824 | 0.050 |
Why?
|
Africa South of the Sahara | 2 | 2021 | 742 | 0.050 |
Why?
|
Withholding Treatment | 2 | 2019 | 613 | 0.050 |
Why?
|
Genome, Viral | 2 | 2020 | 658 | 0.050 |
Why?
|
Killer Cells, Natural | 2 | 2022 | 2203 | 0.050 |
Why?
|
Vaginal Smears | 1 | 2024 | 495 | 0.050 |
Why?
|
Anemia | 1 | 2011 | 1511 | 0.050 |
Why?
|
Risk Factors | 9 | 2020 | 74359 | 0.050 |
Why?
|
Feces | 2 | 2018 | 1455 | 0.050 |
Why?
|
Case-Control Studies | 5 | 2018 | 22053 | 0.050 |
Why?
|
Treatment Outcome | 6 | 2018 | 65017 | 0.050 |
Why?
|
Genes, pol | 1 | 2020 | 52 | 0.050 |
Why?
|
Drug Therapy, Combination | 3 | 2021 | 6498 | 0.050 |
Why?
|
Rh-Hr Blood-Group System | 1 | 2021 | 65 | 0.050 |
Why?
|
Vitamin D | 1 | 2014 | 3291 | 0.050 |
Why?
|
Pilot Projects | 3 | 2021 | 8555 | 0.040 |
Why?
|
Databases, Nucleic Acid | 1 | 2021 | 204 | 0.040 |
Why?
|
Polymerase Chain Reaction | 2 | 2020 | 6068 | 0.040 |
Why?
|
Algorithms | 3 | 2020 | 13981 | 0.040 |
Why?
|
Proportional Hazards Models | 3 | 2019 | 12531 | 0.040 |
Why?
|
Polymorphism, Genetic | 1 | 2010 | 4291 | 0.040 |
Why?
|
Genes, MHC Class II | 1 | 2020 | 451 | 0.040 |
Why?
|
Kenya | 1 | 2022 | 749 | 0.040 |
Why?
|
Monocytes | 2 | 2019 | 2575 | 0.040 |
Why?
|
Anti-Bacterial Agents | 1 | 2017 | 7408 | 0.040 |
Why?
|
Vaccination | 2 | 2023 | 3361 | 0.040 |
Why?
|
Acquired Immunodeficiency Syndrome | 1 | 2007 | 2197 | 0.040 |
Why?
|
AIDS Serodiagnosis | 1 | 2020 | 216 | 0.040 |
Why?
|
Pyrimidines | 2 | 2023 | 3016 | 0.040 |
Why?
|
Interferon-gamma | 2 | 2020 | 3157 | 0.040 |
Why?
|
pol Gene Products, Human Immunodeficiency Virus | 1 | 2018 | 39 | 0.040 |
Why?
|
Laboratories | 1 | 2022 | 462 | 0.040 |
Why?
|
Microbial Sensitivity Tests | 2 | 2018 | 1949 | 0.040 |
Why?
|
Alanine | 1 | 2021 | 606 | 0.040 |
Why?
|
Transcription, Genetic | 1 | 2012 | 7593 | 0.040 |
Why?
|
Virus Internalization | 2 | 2012 | 494 | 0.040 |
Why?
|
Animals | 5 | 2023 | 167963 | 0.040 |
Why?
|
Postpartum Period | 2 | 2016 | 1167 | 0.040 |
Why?
|
Ribavirin | 1 | 2019 | 396 | 0.040 |
Why?
|
Aged | 4 | 2024 | 169152 | 0.040 |
Why?
|
Chromosomes, Human | 1 | 2019 | 442 | 0.040 |
Why?
|
Telemedicine | 1 | 2015 | 3018 | 0.040 |
Why?
|
Sequence Analysis, RNA | 2 | 2018 | 2005 | 0.040 |
Why?
|
Health Services Accessibility | 1 | 2015 | 5397 | 0.040 |
Why?
|
Likelihood Functions | 1 | 2020 | 987 | 0.040 |
Why?
|
BCG Vaccine | 1 | 2020 | 371 | 0.040 |
Why?
|
Recombination, Genetic | 1 | 2022 | 1526 | 0.040 |
Why?
|
Clinical Laboratory Techniques | 1 | 2022 | 749 | 0.030 |
Why?
|
Amino Acids | 1 | 2022 | 1714 | 0.030 |
Why?
|
Drug Resistance | 1 | 2022 | 1617 | 0.030 |
Why?
|
Sequence Alignment | 1 | 2020 | 2176 | 0.030 |
Why?
|
Neonatal Screening | 1 | 2020 | 595 | 0.030 |
Why?
|
United Nations | 1 | 2016 | 151 | 0.030 |
Why?
|
Interferon-alpha | 1 | 2019 | 918 | 0.030 |
Why?
|
Escherichia coli | 2 | 2017 | 4219 | 0.030 |
Why?
|
Least-Squares Analysis | 1 | 2015 | 369 | 0.030 |
Why?
|
Birth Weight | 1 | 2023 | 2097 | 0.030 |
Why?
|
Drug Combinations | 1 | 2020 | 2025 | 0.030 |
Why?
|
Neutralization Tests | 1 | 2016 | 728 | 0.030 |
Why?
|
Population Density | 1 | 2014 | 192 | 0.030 |
Why?
|
Phlebotomy | 1 | 2015 | 137 | 0.030 |
Why?
|
Drug Resistance, Microbial | 1 | 2017 | 856 | 0.030 |
Why?
|
Infant, Low Birth Weight | 1 | 2018 | 859 | 0.030 |
Why?
|
Disease Susceptibility | 1 | 2020 | 1791 | 0.030 |
Why?
|
Placenta | 1 | 2023 | 1702 | 0.030 |
Why?
|
Congenital Abnormalities | 1 | 2018 | 704 | 0.030 |
Why?
|
Multivariate Analysis | 2 | 2019 | 12159 | 0.030 |
Why?
|
Awareness | 1 | 2018 | 646 | 0.030 |
Why?
|
Follow-Up Studies | 3 | 2021 | 39261 | 0.030 |
Why?
|
Contraceptives, Oral | 1 | 2016 | 554 | 0.030 |
Why?
|
Papillomavirus Vaccines | 1 | 2019 | 495 | 0.030 |
Why?
|
Double-Blind Method | 2 | 2017 | 12427 | 0.030 |
Why?
|
Interleukin-2 | 1 | 2020 | 1889 | 0.030 |
Why?
|
Intention | 1 | 2016 | 345 | 0.030 |
Why?
|
Ultrasonography, Prenatal | 1 | 2021 | 1745 | 0.030 |
Why?
|
Peripartum Period | 1 | 2014 | 138 | 0.030 |
Why?
|
Nucleic Acid Amplification Techniques | 1 | 2015 | 330 | 0.030 |
Why?
|
T-Lymphocytes | 2 | 2020 | 10181 | 0.030 |
Why?
|
Antibiotic Prophylaxis | 1 | 2017 | 643 | 0.030 |
Why?
|
Cytopathogenic Effect, Viral | 1 | 2012 | 151 | 0.030 |
Why?
|
Cost-Benefit Analysis | 2 | 2015 | 5508 | 0.030 |
Why?
|
Cardiovascular Diseases | 1 | 2018 | 15757 | 0.030 |
Why?
|
Gestational Age | 1 | 2021 | 3565 | 0.020 |
Why?
|
Medicine, African Traditional | 1 | 2012 | 29 | 0.020 |
Why?
|
Pregnancy Proteins | 1 | 2013 | 222 | 0.020 |
Why?
|
Virus Attachment | 1 | 2012 | 55 | 0.020 |
Why?
|
Fibrin Fibrinogen Degradation Products | 1 | 2014 | 418 | 0.020 |
Why?
|
Delivery, Obstetric | 1 | 2019 | 932 | 0.020 |
Why?
|
Neutropenia | 1 | 2017 | 884 | 0.020 |
Why?
|
HIV Core Protein p24 | 1 | 2012 | 245 | 0.020 |
Why?
|
Plant Roots | 1 | 2012 | 114 | 0.020 |
Why?
|
Models, Molecular | 1 | 2022 | 5434 | 0.020 |
Why?
|
Antibodies, Viral | 1 | 2023 | 3143 | 0.020 |
Why?
|
Health Knowledge, Attitudes, Practice | 2 | 2018 | 3986 | 0.020 |
Why?
|
Plants, Medicinal | 1 | 2012 | 166 | 0.020 |
Why?
|
Continuity of Patient Care | 1 | 2018 | 1066 | 0.020 |
Why?
|
Placebos | 1 | 2015 | 1668 | 0.020 |
Why?
|
Codon | 1 | 2013 | 602 | 0.020 |
Why?
|
Community Health Services | 1 | 2016 | 654 | 0.020 |
Why?
|
Family Characteristics | 1 | 2016 | 1001 | 0.020 |
Why?
|
Goals | 1 | 2016 | 708 | 0.020 |
Why?
|
Herpes Genitalis | 1 | 2011 | 142 | 0.020 |
Why?
|
Antirheumatic Agents | 1 | 2020 | 1374 | 0.020 |
Why?
|
Receptors, CCR5 | 1 | 2012 | 488 | 0.020 |
Why?
|
Lactation | 1 | 2012 | 397 | 0.020 |
Why?
|
Herpesvirus 2, Human | 1 | 2011 | 191 | 0.020 |
Why?
|
Sex Distribution | 1 | 2015 | 2295 | 0.020 |
Why?
|
Suppression, Genetic | 1 | 2010 | 190 | 0.020 |
Why?
|
Phytotherapy | 1 | 2012 | 295 | 0.020 |
Why?
|
Vascular Endothelial Growth Factor Receptor-1 | 1 | 2013 | 558 | 0.020 |
Why?
|
Mothers | 1 | 2020 | 2186 | 0.020 |
Why?
|
Cost of Illness | 1 | 2019 | 1940 | 0.020 |
Why?
|
Infant Nutritional Physiological Phenomena | 1 | 2012 | 351 | 0.020 |
Why?
|
Tanzania | 1 | 2014 | 1383 | 0.020 |
Why?
|
Alleles | 1 | 2020 | 6898 | 0.020 |
Why?
|
HLA-B Antigens | 1 | 2010 | 331 | 0.020 |
Why?
|
High-Throughput Nucleotide Sequencing | 1 | 2021 | 3616 | 0.020 |
Why?
|
Ambulatory Care Facilities | 1 | 2015 | 926 | 0.020 |
Why?
|
Risk-Taking | 1 | 2014 | 998 | 0.020 |
Why?
|
Perinatal Care | 1 | 2011 | 242 | 0.020 |
Why?
|
Seasons | 1 | 2014 | 1522 | 0.020 |
Why?
|
Sequence Homology | 1 | 2008 | 195 | 0.020 |
Why?
|
Survival Analysis | 2 | 2013 | 10182 | 0.020 |
Why?
|
Interleukin-10 | 1 | 2014 | 1175 | 0.020 |
Why?
|
Capsid Proteins | 1 | 2011 | 467 | 0.020 |
Why?
|
Polymorphism, Single Nucleotide | 2 | 2022 | 15789 | 0.020 |
Why?
|
Gene Expression | 1 | 2021 | 7588 | 0.020 |
Why?
|
Sequence Homology, Amino Acid | 1 | 2012 | 2753 | 0.020 |
Why?
|
Population Surveillance | 1 | 2018 | 2608 | 0.020 |
Why?
|
Africa, Southern | 1 | 2007 | 59 | 0.020 |
Why?
|
Protease Inhibitors | 1 | 2011 | 755 | 0.020 |
Why?
|
Reagent Kits, Diagnostic | 1 | 2009 | 238 | 0.020 |
Why?
|
Laboratories, Hospital | 1 | 2009 | 193 | 0.020 |
Why?
|
Drug Tolerance | 1 | 2009 | 369 | 0.020 |
Why?
|
Genetic Heterogeneity | 1 | 2011 | 724 | 0.020 |
Why?
|
Statistics, Nonparametric | 1 | 2013 | 2852 | 0.020 |
Why?
|
Carcinoma, Hepatocellular | 1 | 2019 | 2299 | 0.020 |
Why?
|
Family Planning Services | 1 | 2010 | 265 | 0.020 |
Why?
|
Lactates | 1 | 2007 | 404 | 0.020 |
Why?
|
Computer Simulation | 1 | 2020 | 6218 | 0.020 |
Why?
|
Health Personnel | 1 | 2020 | 3310 | 0.020 |
Why?
|
Motivation | 1 | 2016 | 1993 | 0.020 |
Why?
|
Risk | 1 | 2018 | 9631 | 0.020 |
Why?
|
Developmental Disabilities | 1 | 2014 | 1504 | 0.020 |
Why?
|
Selection, Genetic | 1 | 2010 | 869 | 0.020 |
Why?
|
Socioeconomic Factors | 1 | 2019 | 7806 | 0.020 |
Why?
|
Residence Characteristics | 1 | 2015 | 2062 | 0.020 |
Why?
|
Demography | 1 | 2010 | 1650 | 0.020 |
Why?
|
Linear Models | 1 | 2015 | 5877 | 0.020 |
Why?
|
Drug Administration Schedule | 1 | 2013 | 4899 | 0.020 |
Why?
|
Point Mutation | 1 | 2010 | 1594 | 0.020 |
Why?
|
T-Lymphocytes, Cytotoxic | 1 | 2011 | 1765 | 0.010 |
Why?
|
Research Design | 1 | 2020 | 6180 | 0.010 |
Why?
|
Protein Binding | 1 | 2016 | 9335 | 0.010 |
Why?
|
Liver Neoplasms | 1 | 2019 | 4319 | 0.010 |
Why?
|
Enzyme-Linked Immunosorbent Assay | 1 | 2010 | 3804 | 0.010 |
Why?
|
Immunologic Factors | 1 | 2012 | 1588 | 0.010 |
Why?
|
Child Development | 1 | 2014 | 2285 | 0.010 |
Why?
|
Tumor Necrosis Factor-alpha | 1 | 2014 | 4357 | 0.010 |
Why?
|
Politics | 1 | 2009 | 814 | 0.010 |
Why?
|
Phenotype | 1 | 2019 | 16546 | 0.010 |
Why?
|
Randomized Controlled Trials as Topic | 1 | 2018 | 10344 | 0.010 |
Why?
|
Sex Factors | 1 | 2014 | 10547 | 0.010 |
Why?
|
Peptide Fragments | 1 | 2012 | 5125 | 0.010 |
Why?
|
Dose-Response Relationship, Drug | 1 | 2012 | 10827 | 0.010 |
Why?
|
Acute Disease | 1 | 2009 | 7269 | 0.010 |
Why?
|
Patient Compliance | 1 | 2009 | 2688 | 0.010 |
Why?
|
Age Factors | 1 | 2015 | 18416 | 0.010 |
Why?
|
Logistic Models | 1 | 2013 | 13314 | 0.010 |
Why?
|
Cells, Cultured | 1 | 2012 | 18957 | 0.010 |
Why?
|
Patient Selection | 1 | 2007 | 4283 | 0.010 |
Why?
|
Severity of Illness Index | 1 | 2011 | 15840 | 0.010 |
Why?
|
Cell Line | 1 | 2006 | 15620 | 0.010 |
Why?
|